Bevacizumab In 2004, the FDA approved bevacizumab, which is a full-length monoclonal antibody against VEGF, for the treatment of metastatic colorectal cancer. It has also been used “off-label” for the treatment of AMD via intravitreal and intravenous administration. Although bevacizumab and ranibizumab are manufactured by the same pharmaceutical company, there are important differences between the drugs: bevacizumab is larger, with 2 antigen-binding domains, contrasted with the smaller ranibizumab with a single domain. In addition, bevacizumab costs substantially less, impacting its availability to some patients. Because full-length antibodies are not cleared as rapidly as fragment antibodies, intravitreal injections of bevacizumab have a longer systemic half-life than intravitreal injections of ranibizumab (~21 days for bevacizumab vs 2.2 hours for ranibizumab).